Trials / Completed
CompletedNCT06352424
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
A Single-dose, Randomized, Placebo-controlled Phase I Study on the Effects of a Subcutaneous Dose of BI 1820237 and BI 456906, and Combination Thereof on Functional MRI Measurements in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Single-blind, Cross-over Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 456906 | BI 456906 |
| DRUG | BI 1820237 | BI 1820237 |
| DRUG | Placebo for BI 1820237 | Placebo for BI 1820237 |
| DRUG | Placebo for BI 456906 | Placebo for BI 456906 |
Timeline
- Start date
- 2024-04-30
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
- First posted
- 2024-04-08
- Last updated
- 2025-03-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06352424. Inclusion in this directory is not an endorsement.